A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

第3相 実施中（募集終了） NCT05197049

概要

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Percentage of Participants Who Achieved Clinical Remission at Week 12

At Week 12 · Percentage of participants

Percentage of Participants Who Achieved Endoscopic Response at Week 12

At Week 12 · Percentage of participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severe — Janssen Research & Development, LLC
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn' — Janssen Research & Development, LLC
• A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Partic — Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
• PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Celularity Incorporated
• Loss of RESponse to Ustekinumab Treated by Dose Escalation — Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Par — Pfizer

すべての治験